SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
Not Applicable
Not yet recruiting
- Conditions
- Soft Tissue Sarcoma
- First Posted Date
- 2025-07-03
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT07049848
- Locations
- πΊπΈ
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1
Phase 2
Not yet recruiting
- Conditions
- Lung Squamous Cell CarcinomaAnti-PD1/PDL1 Antibody
- Interventions
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT07038915
- Locations
- πΊπΈ
MD Anderson Cancer Center, Houston, Texas, United States
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
Phase 2
Not yet recruiting
- Conditions
- Targeted TherapyIDH1-Mutated MalignanciesMutations
- Interventions
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 68
- Registration Number
- NCT07032727
- Locations
- πΊπΈ
MD Anderson Cancer Center, Houston, Texas, United States
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
Phase 2
Not yet recruiting
- Conditions
- Metastatic Castration Resistant Prostate CancerBone MarrowCytopenia
- Interventions
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT07025512
- Locations
- πΊπΈ
MD Anderson Cancer Center, Houston, Texas, United States
Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)
Phase 2
Not yet recruiting
- Conditions
- Active SurveillanceClear Cell Renal Cell Carcinoma
- Interventions
- Other: Active Surveillance
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 78
- Registration Number
- NCT07023432
- Locations
- πΊπΈ
MD Anderson Cancer Center, Houston, Texas, United States
Phase 2 Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases
Phase 2
Not yet recruiting
- Conditions
- Renal Cell CarcinomaBrain Metastasis
- Interventions
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT07011849
- Locations
- πΊπΈ
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
Phase 1
Not yet recruiting
- Conditions
- Metastatic Triple-Negative Breast Cancer
- Interventions
- First Posted Date
- 2025-06-09
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT07011654
- Locations
- πΊπΈ
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer
Phase 2
Not yet recruiting
- Conditions
- Microsatellite-stable Colorectal CancerStandard of CareNivolumabBevacizumab
- Interventions
- First Posted Date
- 2025-06-09
- Last Posted Date
- 2025-06-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT07011550
- Locations
- πΊπΈ
MD Anderson Cancer Center, Houston, Texas, United States
Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention
Recruiting
- Conditions
- Liver Cancer
- First Posted Date
- 2025-06-08
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT07010315
- Locations
- πΊπΈ
MD Anderson Cancer Center, Houston, Texas, United States
Development of an Educational Patient Decision Aid (Treatments in Advanced Cancer - Decision Aid, TA-DA) to Promote Shared Decision Making for Third-line or Beyond Palliative Systemic Therapy
Not Applicable
Not yet recruiting
- Conditions
- Advanced Cancer
- First Posted Date
- 2025-06-08
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 155
- Registration Number
- NCT07009886
- Locations
- πΊπΈ
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States